Browse our 650+ Publications​

Latest Publications

Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation

Becher LRE., et al.
December 2020
Authors and Affiliates
Laura R E Becher 1,2, Wendy K Nevala 2, Shari Lee Sutor 2, Megan Abergel 3,4,5, Michele M Hoffmann 1, Christopher A Parks 1, Larry R Pease 1, Adam G Schrum 3,4,5, Svetomir N Markovic 2, Diana Gil 3,4,5; 1Department of Immunology, Mayo Clinic Graduate School of Biomedical Sciences, and. 2Department of Oncology, Mayo Clinic, Rochester, MN; and. 3Department of Surgery, School of Medicine. 4Department of Molecular Microbiology & Immunology, School of Medicine, and. 5Department of Bioengineering, College of Engineering, University of Missouri, Columbia, MO.

The T Cell Receptor Repertoire in Neuropsychiatric Systemic Lupus Erythematosus

Moore E., et al.
December 2020
Authors and Affiliates
Erica Moore 1, Michelle W Huang 1, Shweta Jain 2, Samantha A Chalmers 1, Fernando Macian 3, Chaim Putterman 1,4,5,6; 1 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States. 2 Early Discovery and Fundamental Research, Hansoh Bio, Rockville, MD, United States. 3 Department of Pathology, Albert Einstein College of Medicine, New York, NY, United States. 4 Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, United States. 5 Bar-Ilan University Azrieli Faculty of Medicine, Ramat Gan, Israel. 6 Galilee Medical Center, Nahariya, Israel.

Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions

Bozhanova NG., et al.
November 2020
Authors and Affiliates
Nina G Bozhanova 1,2, Amandeep K Sangha 1,2, Alexander M Sevy 2,3, Pavlo Gilchuk 3, Kai Huang , 5, Rachel S Nargi 3, Joseph X Reidy 3, Andrew Trivette 3, Robert H Carnahan 3,6, Alexander Bukreyev 4,5,7, James E Crowe Jr 3,6,8, Jens Meiler 9,2,10; 1 Department of Chemistry, Vanderbilt University, Nashville, TN 37235. 2 Center for Structural Biology, Vanderbilt University, Nashville, TN 37235. 3 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232. 4 Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555. 5 Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550. 6 Department of Pediatrics, Vanderbilt University Medical Center, Nashville TN 37232. 7 Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555. 8 Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232. 9 Department of Chemistry, Vanderbilt University, Nashville, TN 37235; jens@meilerlab.org. 10 Institute for Drug Discovery, Leipzig University Medical School, Leipzig, SAC 04103, Germany.

Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease

Strobl J., et al.
November 2020
Authors and Affiliates
Johanna Strobl 1, Ram Vinay Pandey 1, Thomas Krausgruber 2, Nadine Bayer 1, Lisa Kleissl 1,3, Bärbel Reininger 1, Pablo Vieyra-Garcia 4, Peter Wolf 4, Maaia-Margo Jentus 1, Margit Mitterbauer 5, Philipp Wohlfarth 5, Werner Rabitsch 5, Georg Stingl 1, Christoph Bock 2,3,6, Georg Stary 7,2,3; 1 Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria. 2 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria. 3 Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, 1090 Vienna, Austria. 4 Department of Dermatology and Venereology, Medical University of Graz, 8036 Graz, Austria. 5 Department of Internal Medicine I, Hematopoietic Stem Cell Transplantation Unit, Medical University of Vienna, 1090 Vienna, Austria. 6 Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. 7 Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria. georg.stary@meduniwien.ac.at.

Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis

Jiang R., et al.
November 2020
Authors and Affiliates
Ruoyi Jiang 1, Kenneth B Hoehn 2, Casey S Lee 3, Minh C Pham 1, Robert J Homer 2,4, Frank C Detterbeck 5, Inmaculada Aban 6, Leslie Jacobson 7, Angela Vincent 7, Richard J Nowak 3, Henry J Kaminski 8, Steven H Kleinstein 9,2,10, Kevin C O'Connor 9,3; 1 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511. 2 Department of Pathology, Yale University School of Medicine, New Haven, CT 06511. 3 Department of Neurology, Yale University School of Medicine, New Haven, CT 06511. 4 Pathology & Laboratory Medicine Service, VA CT Health Care System, West Haven, CT 06516. 5 Department of Surgery, Yale University School of Medicine, New Haven, CT 06511. 6 Department of Biostatistics, University of Alabama, Birmingham, AL 35294. 7 Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, OX1 2JD Oxford, United Kingdom. 8 Department of Neurology, The George Washington University, Washington, DC 20052. 9 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511; steven.kleinstein@yale.edu kevin.oconnor@yale.edu. 10 Interdepartmental Program in Computational Biology & Bioinformatics, Yale University, New Haven, CT 06511

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

Meurer T., et al.
November 2020
Authors and Affiliates
Thuja Meurer 1, Pietro Crivello 2, Maximilian Frederik Metzing 1, Michel Kester 3, Dominik A Megger 4, Weiqiang Chen 4, P A van Veelen 5, Peter van Balen 3, Astrid Westendorf 6, Georg Homa 1, Sophia E Layer 1, Amin T Turki 1, Marieke Griffioen 3, Peter A Horn 1, Barbara Sitek 7, Dietrich W Beelen 8, J H Frederik Falkenburg 9, Esteban Arrieta-Bolaños 10, Katharina Fleischhauer 10; 1 University Hospital Essen, Essen, Germany. 2 Essen University Hospital, Essen, Germany. 3 Leiden University Medical Center, Leiden, Netherlands. 4 Medical Proteome Center, Ruhr University Bochum, Bochum, Germany. 5 Centre for Medical Systems Biology, Leiden University Medical Center, Leiden, Netherlands. 6 University of Duisburg-Essen, University Hospital Essen, Essen, Germany. 7 Ruhr-University Bochum. 8 University Hospital of Essen, Essen, Germany. 9 Leiden University of Medical Center, Leiden, Netherlands. 10 German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Germany.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Reddy SM., el at.
November 2020
Authors and Affiliates
Sangeetha M Reddy 1,2, Alexandre Reuben 3,4, Souptik Barua 5,6, Hong Jiang 3, Shaojun Zhang 7, Linghua Wang 7, Vancheswaran Gopalakrishnan 3, Courtney W Hudgens 8, Michael T Tetzlaff 8,9, James M Reuben 10,11, Takahiro Tsujikawa 12,13, Lisa M Coussens 12, Khalida Wani 8, Yan He 8, Lily Villareal 11, Anita Wood 11, Arvind Rao 6,14, Wendy A Woodward 11,15, Naoto T Ueno 16,11, Savitri Krishnamurthy 17,18, Jennifer A Wargo 19,7, Elizabeth A Mittendorf 20,21,22; 1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2 Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. 3 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5 Department of Electrical and Computer Engineering, Rice University, Houston, Texas. 6 Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan. 7 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 10 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11 Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. 12 Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon. 13 Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. 14 Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 15 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 16 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 17 Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 18 Department of Breast Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 19 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 20 Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org. 21 Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 22 Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Keymeulen B., et al.
November 2020
Authors and Affiliates
Bart Keymeulen 1,2, André van Maurik 3, Dave Inman 3, João Oliveira 4, Rene McLaughlin 5, Rachel M Gittelman 6, Bart O Roep 7,8, Pieter Gillard 9, Robert Hilbrands 10,11, Frans Gorus 10,11, Chantal Mathieu 9, Ursule Van de Velde 10,11, Nicolas Wisniacki 3, Antonella Napolitano 12; 1 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium. bart.keymeulen@vub.be. 2 Belgian Diabetes Registry, Brussels, Belgium. bart.keymeulen@vub.be. 3 GlaxoSmithKline Medicines Research Centre, Stevenage, UK. 4 GlaxoSmithKline, Global Clinical Operations, Cambridge, UK. 5 Department of Immunology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. 6 Adaptive Biotechnologies, Seattle, WA, USA. 7 Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. 8 Department of Diabetes Immunology, Diabetes & Metabolism Research Institute, Beckman Research Institute at the City of Hope, Duarte, CA, USA. 9 Department of Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium. 10 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium. 11 Belgian Diabetes Registry, Brussels, Belgium. 12 GlaxoSmithKline Medicines Research Centre, Stevenage, UK. Antonella.2.napolitano@gsk.com.

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Reinke S., et al.
November 2020
Authors and Affiliates
Sarah Reinke 1, Paul J Bröckelmann 2, Ingram Iaccarino 1, Maria Alejandra Garcia-Marquez 2, Sven Borchmann 3, Franziska Jochims 4, Michaela Kotrova 5, Karol Pal 6, Monika Brüggemann 5, Elena Hartmann 7, Stephanie Sasse 8, Carsten Kobe 9, Stephan Mathas 10, Martin Soekler 11, Ulrich Keller 12, Matthias Bormann 13, Andreas Zimmermann 14, Julia Richter 15, Michael Fuchs 3, Bastian von Tresckow 16, Peter Borchmann 17, Hans Schlößer 18, Michael von Bergwelt-Baildon 19, Andreas Rosenwald 20, Andreas Engert 21, Wolfram Klapper 22; 1 University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. 2 University Hospital of Cologne, Cologne, Germany. 3 University of Cologne, Cologne, Germany. 4 University Hospital Schleswig-Holstein, Campus Kiel, Groß Grönau, Germany. 5 Universitätsklinikum Schleswig-Holstein, Kiel, Germany. 6 University Hospital Schleswig-Holstein, Kiel, Germany. 7 University of Würzburg, Würzburg, Germany. 8 Cologne, Germany. 9 Department of Nuclear Medicine, University of Cologne, Cologne, Germany, Cologne, Germany. 10 Max-Delbrück-Center for Molecular Medicine, Berlin, Germany. 11 Hospital Thun, Thun, Switzerland. 12 Charite - Universitätsmedizin Berlin, Berlin, Germany. 13 Klinikum Bremen-Mitte, Bremen, Germany. 14 University Hospital LMU Munich, Munich, Germany. 15 Christian-Albrechts University Kiel, Kiel, Germany. 16 University Hospital Essen, Germany. 17 Uniklinik Koeln, Koeln, Germany. 18 University Hospital of Cologne. 19 University Hospital LMU, Munich, Germany. 20 University of Wuerzburg, Wuerzburg, Germany. 21 University Hospital of Cologne, Koeln, Germany. 22 Department of Pathology, Kiel, Kiel, Germany.

Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis

Durgin JS., et al.
November 2020
Authors and Affiliates
Joseph S Durgin 1, Neha N Jariwala 1, Maria Wysocka 1, Kevin K Zhang 1, Amit Maity 2, Bernice Benoit 1, John P Plastaras 2, Daniel J Lewis 1, Jaclyn M Rosenthal 1, Jessica E Teague 3, Sara Berg 1, Christina Del Guzzo 1, Ellen J Kim 1, Carmela Vittorio 1, Paul L Haun 1, Sara S Samimi 1, Jennifer Villasenor-Park 1, Joanne Inverso 1, Rachael A Clark 3, Alain H Rook 1; 1 Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 2 Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA